Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDIntercept Pharma Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
Intercept Pharma Earnings Date And Information
Intercept Pharma last posted its earnings results on Tuesday, November 7th, 2023. The company reported $-0.07 earnings per share for the quarter, topping analysts' consensus estimates of $-0.27 by $0.2. The company had revenue of 88.79 M for the quarter and had revenue of 285.71 M for the year. Intercept Pharma has generated $3 earnings per share over the last year ($3.4 diluted earnings per share) and currently has a price-to-earnings ratio of 5.58. Intercept Pharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Intercept Pharma Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2023 | Q3 2023 | N/A | -$0.07 | N/A | $88.02 M | $88.79 M |
| 08/02/2023 | Q2 2023 | -$0.56 | -$0.14 | 0.42 | $79.57 M | $83.72 M |
| 04/27/2023 | Q1 2023 | -$0.57 | -$0.71 | -0.14 | $80.35 M | $67.96 M |
| 03/02/2023 | Q4 2022 | -$0.53 | -$0.49 | 0.04 | $93.51 M | $77.22 M |
| 11/01/2022 | Q3 2022 | $5.11 | $5.07 | -0.04 | $89.99 M | $77.59 M |
| 08/03/2022 | Q2 2022 | -$0.53 | -$0.25 | 0.28 | $95.72 M | $71.76 M |
| 05/06/2022 | Q1 2022 | -$0.89 | -$0.58 | 0.31 | $120.08 M | $88.58 M |
| 03/02/2022 | Q4 2021 | -$1.26 | -$1.23 | 0.03 | N/A | $92.40 M |
| 11/03/2021 | Q3 2021 | -$1.00 | -$0.11 | 0.89 | $81.81 M | $92.83 M |
| 07/29/2021 | Q2 2021 | -$1.24 | -$0.33 | 0.91 | $82.68 M | $96.58 M |
| 05/06/2021 | Q1 2021 | -$1.53 | -$1.22 | 0.31 | $81.14 M | $81.66 M |
| 02/25/2021 | Q4 2020 | -$1.55 | -$1.58 | -0.03 | $85.01 M | $83.27 M |
| 11/09/2020 | Q3 2020 | -$1.96 | -$2.01 | -0.05 | $76.22 M | $79.52 M |
| 08/10/2020 | Q2 2020 | -$2.94 | -$1.92 | 1.02 | $117.48 M | $77.25 M |
| 05/11/2020 | Q1 2020 | -$2.94 | -$2.86 | 0.08 | $73.67 M | $72.65 M |
| 02/25/2020 | Q4 2019 | -$2.56 | -$2.99 | -0.43 | $63.85 M | $71.50 M |
| 11/05/2019 | Q3 2019 | -$2.35 | -$2.59 | -0.24 | $58.12 M | $61.95 M |
| 08/08/2019 | Q2 2019 | N/A | -$2.28 | N/A | $75.61 M | $66.30 M |
| 05/08/2019 | Q1 2019 | -$2.57 | -$3.03 | -0.46 | $43.46 M | $52.25 M |
| 03/01/2019 | Q4 2018 | N/A | -$2.97 | N/A | $44.49 M | $53.28 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Intercept Pharma Earnings: FAQ's
In the previous quarter, Intercept Pharma (:ICPT) reported $-0.07 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.27 by $0.2.
The conference call for Intercept Pharma's latest earnings report can be listened to online.
The conference call transcript for Intercept Pharma's latest earnings report can be read online.
Intercept Pharma (:ICPT) has a recorded annual revenue of $285.71 M.
Intercept Pharma (:ICPT) has a recorded net income of $115.17 M.Intercept Pharma has generated $3.41 earnings per share over the last four quarters.
Intercept Pharma (:ICPT) has a price-to-earnings ratio of 5.58 and price/earnings-to-growth ratio is -0.04.